Mobileye Announces Participation at the Barclays Global Automotive and Mobility Tech Conference
JERUSALEM–(BUSINESS WIRE)–Mobileye Global Inc. (Nasdaq: MBLY) (“Mobileye”) announced today that Dan Galves, Chief Communications Officer,... Read more.
Keep It Local Business Fund Grants Awarded to Entrepreneurs of Color Across the Country
In Its Second Grant Round, The Nextdoor Kind Foundation Provides Microgrant Funding to Small Business Owners of Color to Make a Big Impact in Their Communities SAN... Read more.
Radian’s Fundraising Campaign for MBA Opens Doors Foundation Surpasses Donation Goal
WAYNE, Pa.–(BUSINESS WIRE)–Radian Group Inc. (NYSE: RDN) today announced that its annual “Opens Doors Opens Hearts” fundraising campaign... Read more.
Square and Afterpay Sellers Hit Record-Breaking Black Friday and Cyber Monday With 70M Transactions
Globally, the peak minute of shopping occurred on Black Friday at 2:09 pm ET on November 24, 2023 Cities with the largest volume of sales were New York, Los Angeles,... Read more.
B2B Businesses Beware: Pivotree Report Finds New Buying Behavior is Here to Stay
Report from Pivotree and Spryker revealed 90% of respondents have seen increase in demand for digital B2B buying experiences in past two years TORONTO–(BUSINESS... Read more.
Trailer and Cargo Container Tracking Report 2023: Installed Base of Active Cargo Tracking Units to Reach 27 Million by 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Trailer and Cargo Container Tracking – 11th Edition” report has been added to ResearchAndMarkets.com’s... Read more.
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod®... Read more.
Organigram Increases Investment in Phylos After Successful Milestone Achievement
Organigram to advance the conversion of its grow rooms with custom designed, F1 Hybrid seeds Organigram expects to soon be able to begin low-cost production of high-potency,... Read more.
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
Phase 2a placebo-controlled study to enroll approximately 30 patients with moderate to severe atopic dermatitis (AD) Study supported by preclinical findings, showing... Read more.
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
BRUKINSA® (zanubrutinib) continues to show progression free survival (PFS) benefit compared with ibrutinib in extended follow-up of patients with relapsed/refractory... Read more.